ArticleJournal of parasitic diseases : official organ of the Indian Society for Parasitology2025
Efficacy of nitazoxanide, ivermectin and albendazole in treatment of cryptosporidiosis in immunosuppressed mice.
Article in Journal of parasitic diseases : official organ of the Indian Society for Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Transcriptomic Profiling and In Vitro Evaluation of Garcinia Mangostana Phytochemicals Against Cryptosporidium Parvum.Cell biochemistry and biophysics · 2026Article
- Therapeutic Efficacy of Albendazole in Neonatal Calves Naturally Infected withPathogens (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptosporidiosis is one of the main causes of fatal watery diarrhea, especially in immunocompromised patients worldwide. Although nitazoxanide (NTZ) is the only effective FDA approved drug for cryptosporidiosis, it is partially effective in immunocompromised patients. So, there is an urgent need for new alternatives for treating cryptosporidiosis in those patients. The present study aims to assess the efficacy of ivermectin (IVM) and albendazole (ALB) as compared to NTZ and their combinations in treatment of cryptosporidiosis in immunosuppressed infected mice. Mice were divided into 7 groups (G) with 10 mice each; GI: treated with NTZ. GII: treated with IVM. GIII: treated with ALB. GIV: treated with combined NTZ and IVM. GV: treated with combined NTZ and ALB. GVI: non-infected non-treated (negative control). GVII: infected non-treated (positive control). Parasitological, histopathological, and immunological studies were done for all studied groups. The combined therapy of NTZ and IVM showed the best results in reducing the oocysts shedding (reduction rate of 91.9%), healing the histopathological inflammatory changes of ileum, in addition to enhancing the cellular immune response by marked elevation of serum INF-γ levels as compared to the other treatment regimens. Therefore, we concluded that this synergistic combination is promising in controlling cryptosporidiosis in immunocompromised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.